Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $69.12 and last traded at $72.96, with a volume of 1291815 shares trading hands. The stock had previously closed at $81.26.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the company. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Truist Financial decreased their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday. Finally, B. Riley decreased their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $131.20.
Check Out Our Latest Stock Analysis on LNTH
Lantheus Trading Down 3.7%
The company's fifty day moving average price is $79.04 and its 200-day moving average price is $89.57. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The stock has a market cap of $4.90 billion, a price-to-earnings ratio of 20.16 and a beta of 0.12.
Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business's revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.69 EPS. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.
Insider Buying and Selling
In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.50% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of LNTH. State of Michigan Retirement System grew its position in Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after buying an additional 100 shares during the period. Signaturefd LLC boosted its stake in shares of Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 116 shares in the last quarter. Intrust Bank NA grew its position in shares of Lantheus by 2.9% during the 1st quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock valued at $431,000 after acquiring an additional 125 shares during the period. Avantax Advisory Services Inc. grew its position in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after acquiring an additional 132 shares during the period. Finally, Foundry Partners LLC raised its holdings in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after purchasing an additional 133 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.
Lantheus Company Profile
(
Get Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
See Also
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
